TriSalus Life shares surge 29% on FDA device clearance

TriSalus Life Sciences shares surged by 29% following the company's announcement of receiving FDA 510(k) clearance for its new device, TriNav Advance. The device, a part of TriSalus' Pressure-Enabled Drug Delivery portfolio, expands the company's offerings by providing access to small, distal vessels. TriNav Advance can be used in two configurations: telescoping mode, which uses a compatible microcatheter for selective delivery to smaller, distal vessels, and high-flow mode, which functions like a standard TriNav device without an additional microcatheter.

This addition to the company's device portfolio allows interventional radiologists to pair TriNav Advance with a compatible microcatheter of their choice, providing flexibility across a broader range of procedures and anatomies. The new device can be used in liver-directed therapy cases, with an indication that supports a broader range of embolization procedures beyond the liver.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.